Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
28 January, 2022 02:02 IST
Lupin enters into pact with Biomm
Source: IRIS | 06 Dec, 2021, 07.12PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Lupin, one of the leading pharmaceutical companies in India, have entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil. Under the terms of agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil.

Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) through a filing using the 351(k) pathway.

Pegfilgrastim is indicated to reduce the duration of neutropenia and the Incidence of febrile neutropenia in patients receiving chemotherapy.

Shares of the company declined Rs 15.15, or 1.74%, to settle at Rs 857.95.  The total volume of shares traded was 55,560 at the BSE (Monday). 

 Post Comment
Name Email
Security Code type    into this box
Related Articles
Zensar Technologies Q3FY22 Review- Long term prospect looks attractive - 27-Jan-2022 15:00
Maruti Suzuki India Q3FY22 Review-Super bullish and expect 24% upside - 27-Jan-2022 14:33
Federal Bank Q3FY22 Review-Stressed assets stable at 2.6%; RoA at 1% - 27-Jan-2022 14:21
Welspun India joins global coalition to undertake climate action - 27-Jan-2022 13:03
Maruti Suzuki: Above estimate; strong recovery in market share and margin - 27-Jan-2022 12:49
APL Apollo Tubes Q3FY22 Review-Margin strong despite weak volumes - 27-Jan-2022 10:44
Cera Sanitaryware Q3FY22 Review-A positive surprise on margins front; Buy - 26-Jan-2022 11:01
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer